VALLEY FORGE, Pa., May 13, 2010 (BUSINESS WIRE) --AmerisourceBergen Corporation (NYSE:ABC) today announced that Kathleen
W. Hyle, 51, has been elected to its Board of Directors. The election,
effective today, increases the number of AmerisourceBergen directors
from eight to nine. Ms. Hyle was also appointed to the Audit and
Corporate Responsibility Committee of the Board.
Since 2008, Ms. Hyle has been Senior Vice President of Constellation
Energy (NYSE:CEG) and Chief Operating Officer of Constellation Energy
Resources. In this capacity, Ms. Hyle oversees the operations and
strategic direction of the company's commercial businesses and its
non-nuclear and renewables generation fleet. This includes the nation's
leading customer supply business, Constellation NewEnergy, which
provides energy services and solutions to wholesale and retail
customers; a commodities portfolio management and trading operation; and
a diversified fleet of generating units located in the United States and
Canada.
She joined Constellation Energy in 2003 and prior to her current role
was Senior Vice President of Finance and Chief Financial Officer for
Constellation Energy Nuclear Group and for UniStar Nuclear Energy, LLC,
a strategic joint venture between Constellation Energy and EDF. She has
held other senior-level finance positions at Constellation.
Prior to joining Constellation Energy, Ms. Hyle held the Chief Financial
Officer position with ANC Rental Corp., the parent company of Alamo
Rent-A-Car and National Rent-A-Car, and Vice President and Treasurer
positions with AutoNation Inc. and Black and Decker Corporation.
"Kathi's strong and extensive financial background and broad public
company experience, makes her an excellent addition to the Board," said
Richard C. Gozon, Chairman of the Board of AmerisourceBergen.
Added R. David Yost, President and Chief Executive Officer of
AmerisourceBergen, "Kathi's broad executive experience, solid operations
background, and high performance standards are valuable additions to the
Company."
Ms. Hyle received her Bachelor of Arts degree from Loyola University in
Baltimore.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical services
companies serving the United States, Canada and selected global markets.
Servicing both healthcare providers and pharmaceutical manufacturers in
the pharmaceutical supply channel, the Company provides drug
distribution and related services designed to reduce costs and improve
patient outcomes. AmerisourceBergen's service solutions range from
pharmacy automation and pharmaceutical packaging to reimbursement and
pharmaceutical consulting services. With more than $75 billion in
annualized revenue, AmerisourceBergen is headquartered in Valley Forge,
PA, and employs approximately 10,000 people. AmerisourceBergen is ranked
#24 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
Certain of the statements contained in this press release are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. These statements are based on management's current expectations
and are subject to uncertainty and change in circumstances. Among the
factors that could cause actual results to differ materially from those
projected, anticipated or implied are the following: changes in
pharmaceutical market growth rates; the loss of one or more key customer
or supplier relationships; changes in customer mix; customer
delinquencies, defaults or insolvencies; supplier defaults or
insolvencies; changes in pharmaceutical manufacturers' pricing and
distribution policies or practices; adverse resolution of any contract
or other dispute with customers or suppliers; federal and state
government enforcement initiatives to detect and prevent suspicious
orders of controlled substances and the diversion of controlled
substances; qui tam litigation for alleged violations of laws and
regulations governing the marketing, sale and purchase of pharmaceutical
products or any related litigation, including shareholder derivative
lawsuits; changes in U.S. legislation or regulatory action affecting
pharmaceutical product pricing or reimbursement policies, including
under Medicaid and Medicare; changes in regulatory or clinical medical
guidelines and/or labeling for the pharmaceutical products we
distribute, including certain anemia products; price inflation in
branded pharmaceuticals and price deflation in generics; greater or less
than anticipated benefit from launches of the generic versions of
previously patented pharmaceutical products; significant breakdown or
interruption of our information technology systems; our inability to
implement an enterprise resource planning (ERP) system to handle
business and financial processes within AmerisourceBergen Drug
Corporation's operations and our corporate functions without operating
problems and/or cost overruns; success of integration, restructuring or
systems initiatives; interest rate and foreign currency exchange rate
fluctuations; economic, business, competitive and/or regulatory
developments in Canada, the United Kingdom and elsewhere outside of the
United States, including potential changes in Canadian provincial
legislation affecting pharmaceutical product pricing or service fees or
regulatory action by provincial authorities in Canada to lower
pharmaceutical product pricing or service fees; the impact of
divestitures or the acquisition of businesses that do not perform as we
expect or that are difficult for us to integrate or control; our
inability to successfully complete any other transaction that we may
wish to pursue from time to time; changes in tax legislation or adverse
resolution of challenges to our tax positions; increased costs of
maintaining, or reductions in our ability to maintain, adequate
liquidity and financing sources; volatility and deterioration of the
capital and credit markets; and other economic, business, competitive,
legal, tax, regulatory and/or operational factors affecting our business
generally. Certain additional factors that management believes could
cause actual outcomes and results to differ materially from those
described in forward-looking statements are set forth (i) in Item 1A
(Risk Factors) in the Company's Annual Report on Form 10-K for this
Fiscal Year Ended September 30, 2009 and elsewhere in that report and
(ii) in other reports filed by the Company pursuant to the Securities
Exchange Act of 1934.
SOURCE: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Michael N. Kilpatric, 610-727-7118
[email protected]